This is a summary of the presentation on novel methods of ambulatory physiologic monitoring in patients with neuromuscular disease, presented as part of the program on pulmonary management of pediatric patients with neuromuscular disorders at the 30th annual Carrell-Krusen Neuromuscular Symposium on February 20, 2008. Pediatrics 2009123:S250-S252 R ECENTLY, CONSENSUS GUIDELINES were published for the respiratory care of patients with Duchenne muscular dystrophy and spinal muscular atrophy. These were practice-based guidelines, because the ability to generate evidence-based guidelines is limited because of the relatively rare nature of these diseases. The respiratory care guidelines provide precise recommendations for the timing and extent of respiratory examinations and care, from initial diagnosis through end-oflife directives. The process that produced these guidelines and the recent anesthesia and sedation guidelines, reviewed by Birnkrant in this conference, serves as a model for developing consensus practice parameters thataddress the multisystem involvement seen for many of the muscular dystrophies. [1] [2] [3] [4] [5] In the context of continuous quality improvement, they provided an AIM statement and a clear guide to muscle disorders clinics of the role of pediatric pulmonary evaluation and management (Table 1 www.pediatrics.org/content/vol123/ Supplement_4).
tory inductive plethysmography are shown in Table 2 (www.pediatrics.org/content/vol123/Supplement_4). In our initial survey, the use of the mechanical insufflator/ exsufflator (MI-E), high-frequency chest wall oscillation (HFCWO), and NNIV support were assessed. Data recording used a light-weight respiratory inductive plethysmography device in the home with separate day and sleep algorithm, wrist and wireless oximeter with recording capability, and handheld spirometer. The initial participants were 5 male patients with neuromuscular disease (NMD) who were followed in a muscle disorders clinic and pediatric pulmonary center and were recruited for this pilot study. They were between 8 and 22 years of age and had been introduced to the use of HFCWO, an MI-E device, and NNIV within the previous 18 months. Patients and caretakers reported productive cough, sleep disorders, and anxiety during clinic and home visits. No patient had a tracheostomy or gastrostomy tube. The VivoLogic software (VivoMetrics) collected data with simultaneous screens allowing visual inspection of tidal volume, rib cage movement, abdominal cage movement, electrocardiogram, accelerometers for upright, supine, and lateral positioning and intensity of movement, and oxygen saturation. On the basis of these initial findings, we undertook further study to establish the utility of the LifeShirt in home sleep testing, with attention to the impact of daily use of HFCWO. As a preliminary assessment, this was a single-site study performed in the home setting. All patients resided within a 1-hour drive from the Pediatric Diagnostic Center in Ventura, California, and they resided in rural agricultural, urban, and suburban settings.
The protocol was reviewed by the institutional review board of the Ventura County Medical Center. All patients gave written informed consent or assent before any study-related procedures were performed. Patients with NMD that affected the musculature of the oropharynx and the upper airway or the respiratory musculature who were aged Ն7 years were identified from the pediatric pulmonary clinic of the Pediatric Diagnostic Center. Patients were required to attend a clinic visit to complete the case-report form including medical history, treatments for NMD, and adverse effects of treatment. This was a single-site study.
METHODS
Eight patients with NMD and a history of restrictive lung disease were enrolled in a 90-day trial of HFCWO therapy. Demographic information including diagnosis, gender, age at initiation of MI-E, HFCWO, and NNIV, use of antireflux medications and/or presence of fundoplication, and need for mechanical ventilatory support were recorded (see Table 3 www.pediatrics.org/content/ vol123/Supplement_4). In addition, pulmonary function data, including the most recent spirometry results and measurements of respiratory muscle strength before the initiation of therapies (HFCWO, MI-E, and NNIV), were recorded. Data then were collected to determine the safety, tolerance, and efficacy of the LifeShirt in this patient population. Safety was assessed by noting the occurrence of pulmonary, cardiac, or gastrointestinal complications (eg, pneumothorax, pulmonary hemorrhage, cardiac dysrhythmias, nausea, or vomiting) associated with use of the device. The use of the LifeShirt was considered to be well tolerated if the patient used the device at the prescribed frequency. The patient was classified as intolerant of the device if the patient or caregiver expressed the desire to discontinue use of the LifeShirt for any reason.
Patients were fitted with the wearable LifeShirt system (Fig 3 www. pediatrics.org/content/vol123/ Supplement_4), which incorporates respiratory inductance plethysmography for the noninvasive measurement of volume and timing ventilatory variables. The system also incorporates a single-channel electrocardiogram and a centrally located, 3-axis accelerometer. Data were processed and stored on a compact flash card that was housed within the recorder unit. Patients were fitted at home with a single-lead electroencephalogram (EEG) attached through a serial expansion module at baseline and 30, 60, and 90 days. The subjects slept at home wearing the 8-oz, 260-g shirt that captures ventilation, electrocardiography, pulse oxygen saturation, posture, and EEG data. Sleep studies were scored by certified sleep technicians using VivoLogic software (R and K standard criteria), and the studies underwent independent certified sleep technician reading by using a sleepscoring protocol incorporating respiratory, cardiac, and oximetry data. All studies were reviewed by the principal investigator.
A registered respiratory therapist trained the patients and caregivers in the use of the LifeShirt and in HFCWO therapy with the Vest airway-clearance system (model 104; Hill-Rom, St Paul, MN). The target Vest settings included a frequency of 12 Hz and a pressure setting of 4, adjusted for patient comfort. The subject was monitored throughout the therapy. The subject and caregiver were instructed to interrupt therapy to allow the subject to cough or to clear secretions, if required, and to clear secretions through coughing or suctioning at the completion of therapy. Therapy was performed 3 times per day for 12 minutes per treatment.
Clinical end points included type, frequency, and time distribution of sleep-disordered breathing events such as apneas, hypopneas, arousals, periods of oxygen desaturation, measures of sleep time, stages of sleep, accelerometry, and cardiac and respiratory data.
Subjects were studied at baseline and 30, 60, and 90 days after the initiation of airway-clearance therapy with HFCWO per protocol. Evaluations were performed at 1, 2, and 3 months for pulse oximetry, spirometry, negative inspiratory flow force, and 24-hour wake and sleep continuous ambulatory physiologic monitoring. A central-lead sleep EEG was obtained and integrated with physiologic measures of rapid eye movement (REM) and non-REM sleep.
RESULTS
Subject 5 was withdrawn after 60 days because of reluctance to follow the measurement and intervention protocol, and subject 8 withdrew after 30 days because of anxiety. Both subjects had excessive sweating at night, which led to difficulties in maintaining the EEG leads. Each individual served as his or her own control.
Median respiratory rate over 24 hours improved by 10% within 1 month, and improvement was sustained at the 3-month exit evaluation. Sleep latency and sleeporganization parameters of slow-wave sleep, low delta, theta, and alpha activity, showed continuous improvement over the 90-day trial. One patient had an aspiration-related pneumonia during the 90-day study, with a return to improvement from baseline after resolution of the pulmonary exacerbation.
CONCLUSIONS
It is my hope that, with a source of funding for home sleep testing, the expanded data set available to the NMD clinician will become part of the standard of care in assessing epidemiology, progression of disease, and the impact of current and new therapies. A proposed outline for assessment and intervention is shown in Table 4 (www.pediatrics.org/content/vol123/Supplement_4).
TABLE 1 AIM Statements
All muscle disorder clinic patients will have an annual examination by a pediatric pulmonologist by the age of 4-5 y or by the age at which walking ceases, whichever comes first. When the forced vital capacity is Ͻ1 L, survival time is Ͻ5 years, and more intensive social support for the patient and caregivers will be made available. When the FEV 1 is Ͻ20%, daytime ventilation support will be evaluated. When the FEV 1 is Ͻ40%, a sleep study for consideration for nocturnal ventilation will be performed. When cough peak expiratory flow rate is Ͻ160, airway clearance support, particularly with respiratory infection, will be provided, with evaluation of MI-E and/or HFCWO A daytime low SaO 2 reflects airway disease; asthma, gastroesophageal reflux disease, MI-E, and HFCWO will be considered. The nighttime SaO 2 will be assessed annually, and when reduced, a sleep study will be performed. Poor patient synchrony between rib cage and abdominal effort despite NNIV, resulting in small tidal volumes.
FIGURE 2
Synchrony between rib cage and abdominal effort with noninvasively assisted ventilation, resulting in improved tidal volumes.
FIGURE 3
A patient wearing the LifeShirt apparatus (photographed for publication with permission). 
